Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
Obesity drug prices drop, but high costs and uneven insurance coverage limit access for many.
Despite price drops for obesity drugs Wegovy and Zepbound, access remains challenging.
Monthly costs can still reach $500 for the uninsured, and coverage is uneven, with Medicare and most Medicaid programs not covering these treatments.
Some employers and pharmacy benefit managers have dropped coverage due to costs, while drugmakers are developing pill versions that could further reduce prices.
115 Articles
Los precios de los medicamentos para la obesidad disminuyen, pero los altos costos y la desigualdad de la cobertura de seguros limitan el acceso para muchos.